Grünenthal uses its own and third-party cookies to improve the browsing experience, offer personalized content and improve its services. We use analytics scripts which set a tracking cookie, but we will activate these services only with your consent. If you press the button “Accept”, you consent to the use of these analytics scripts.

You can withdraw your consent at any time. To do so, please modify your configurations on this website by following this link to our privacy statement with the configuration options: Go to settings

I'm ok with this

;

Many chronic conditions are challenging to manage. Here we focus on eight key pain conditions with a high unmet need among patients and/or healthcare professionals.

Our aim here is to provide the pain community with in-depth information about these conditions; from disease understanding to management approaches.

PLEASE SELECT AN INDICATION TO VIEW MORE
 
 

CLUSTER HEADACHE

   

Cluster headache has been described as the most painful condition in humans.1,3 It is characterised by excruciating sharp pain on one side of the head, often around one eye, that lasts from 15 to 180 minutes, up to eight times a day during an episode.3 Cluster headache can be episodic (occurring for periods lasting from 7 days to 1 year, separated by pain-free periods of at least 3 months) or chronic (lasting for 1 year or longer without remission or with remission periods less than 3 months at a time).3 The appearance of cluster headache is often seasonal, focused particularly around the clocks changing to daylight saving time, and they will often occur around the same time each day.1,4,5

 

Quick facts

  • Cluster headache is a rare condition that affects 0.1% of the general population globally.1
  • Men are 4.3 times more likely to suffer from cluster headache than women.2
  • Smoking is a risk factor for cluster headache.1
  • Genetics studies, along with clinical observations and neuroimaging studies, have improved the understanding of cluster headache.1

 

 
 
 
 
 
 
 
 
 

Epidemiology

Globally, cluster headache affects 0.1% of the general population, with an onset ranging from 10 to 68 years.1 It is more common among men than women, with men being 4.3 times more likely to suffer from cluster headaches.2 The episodic form is more common than the chronic form and affects 80–90% of patients with cluster headache.1

Epidemiological estimates of incidence/prevalence of cluster headache per 100,000 based on population-based surveys 

Risk factors

Cluster headache can run in families, although it is difficult to pin down genetic factors in this disease as it is very complex and has a low prevalence.1 Other risk factors include male sex and modifiable lifestyle choices.1,3

 

Cluster headache risk factors 

Causes

Cluster headache attacks and attack periods often display an intriguing seasonal and/or circadian rhythmicity, with peaks in the spring and autumn and attacks occurring around the same time each day.4,5 It is postulated that abnormalities in the hypothalamus, which regulates the body clock, may play a role.4,5


Potential triggers for cluster headache include alcohol, stress, sleep, weather changes and pharmacological triggers 

Signs and symptoms

Cluster headache presents as one-sided pain behind or around one eye.3 Recurrent attacks often focus around the same eye.3 Other symptoms include conjunctival injection, lacrimation, redness, rhinorrhoea/nasal congestion, forehead sweating, eyelid oedema, ptosis and restlessness or agitation;3 people with cluster headache are usually unable to lie down and typically pace.3 Cluster headache often occurs in episodes that last for 1 week to 1 year and are followed by a pain-free remission period of up to 12 months.3


Symptoms of cluster headache include pain in, behind or around one eye, one-sided pain, conjunctival injection, lacrimation, redness of eye on affected side, rhinorrhoea/nasal congestion, facial sweating, eyelid oedema, ptosis, restlessness and agitation 

Pathophysiology

Cluster headache has a complex pathophysiology and the underlying mechanisms are not fully known. Although they present as very different headache disorders, the pathophysiology of cluster headache is similar to that of migraine and the pain in the head is believed to be mediated by activation of neuronal pathways in the trigeminovascular system.1,8 The strongest evidence for alterations in patients with cluster headache is for the hypothalamus, where initial structural and functional changes take place.1 Several neuronal connections exist between the hypothalamus and regions of the trigeminovascular system, with studies indicating that the hypothalamus receives sensory input, including nociceptive information, from areas of the face and cranium innervated by the trigeminal nerve.1

In addition, anatomical and functional links between the hypothalamus and brain areas that are traditionally not considered to be involved in pain processing, such as the occipital cortex and cerebellum, are altered in cluster headache and may have a contributory role in its pathophysiology.1

The autonomic symptoms of cluster headache are thought to be mediated through the trigeminal autonomic reflex, with activation of the trigeminal nerve thought to lead to activation of parasympathetic efferents, producing autonomic symptoms.1

 

Pathways in the pathogenesis of cluster headache 

 

Diagnosis

The diagnosis of cluster headache is based primarily on the patient’s symptoms and involves excluding other primary and secondary headaches.1 Diagnosis is challenging, and patients often consult various specialists prior to receiving the final and true diagnosis.7

There are two types of cluster headache (as defined by the International Classification of Headache Disorders [ICHD]-3 diagnostic criteria for cluster headaches), which are differentiated by their periods of remission between bouts.3 Patients with episodic cluster headache experience pain-free periods of at least 3 months, while those with chronic cluster headache have persistent attacks occurring for more than 1 year without remission or a remission period lasting less than 3 months.3

 

ICHD-3 diagnostic criteria for cluster headache 

 

Management

Guidelines and recommendations

Once effective treatment has been established, future episodes of cluster headache, or maintenance therapy in the case of chronic cluster headache, can be managed by primary care providers, albeit with frequent follow-up.9 Patients with episodic cluster headache in remission should be advised to return promptly at the onset of the next cluster headache episode.9

 

 

SPG: sphenopalatine ganglion.

 

Pharmacological treatments

Although the objective of management in both episodic and chronic cluster headache is total attack suppression, this is not always achievable.9 Three strategies are employed in the treatment of cluster headache. Acute or abortive treatments are used in individuals attacks to stop the pain once it has started.9 Preventive treatments are used for the duration of the cluster period to reduce frequency, duration and severity of individual attacks within that period, and are the mainstay of treatment in the majority of cases.9 Interim (transition) treatments are given at the onset of a cluster period to achieve more rapid response during dose escalation of any of the preventive drugs and may be used while waiting for a preventive treatment to have a therapeutic effect.9,11

Unmet needs

There is a lack of large-scale controlled trials on treatment of cluster headache.1 While genetic studies, clinical observations and neuroimaging studies have improved the understanding of cluster headache,1 further research is necessary to characterise the cause of cluster headache and identify new biomarkers to inform the development of improved treatments.

Resources

 

Click here to register for CHANGE PAIN® and access in-depth educational resources on cluster headache.

Register

  • References

    1. May A et al. Nat Rev Dis Primers. 2018;4:18006.

    2. Fischera M et al. Cephalalgia. 2008;28:614–8.

    3. International Headache Society (IHS). Cephalalgia. 2018;38:1–211.

    4. Naber WC et al. Cephalalgia. 2019;39:1855–66.

    5. de Coo IF et al. Headache. 2019;59:1032–41.

    6. Vollesen AL et al. J Headache Pain. 2018;19:89.

    7. Ljubisavljevic S & Trajkovic JZ. J Neurol. 2019;266:1059–669.

    8. Hoffmann J et al. J Cerebr Blood Flow Metab. 2019;39:573–94.

    9. Steiner TJ et al. J Headache Pain. 2019;20:57.

    10. Robbins MS et al. Headache. 2016;56:1093–106.

    11. Wei DY et al. Pract Neurol. 2019;19:521–8.